A Phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with Gemcitabine in patients with metastatic pancreatic carcinoma.
- Registry ID
- EUCTR2014-004653-14
- Source registry
- EUCTR
- Status
- GB - no longer in EU/EEA
- Phase
- PHASE3
- Sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Start date
- 2015-04-17
- Last update
- 2026-08-16
Conditions
- Metastatic pancreatic carcinoma.
Summary
To assess whether Acelarin is superior to Gemcitabine in terms of overall survival for treatment of patients with metastatic pancreatic carcinoma.
Locations
View on source registry